Fidelity Investments
NVCT icon

Fidelity Investments’s Nuvectis Pharma NVCT Stock Holding History

Fidelity Investments’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.5K Buy
7,568
+358
+5% +$3.07K ﹤0.01% 4059
2025
Q4 		$54.4K Buy
7,210
+7,143
+10,661% +$46.6K ﹤0.01% 4063
2025
Q3 		$403 Buy
67
+62
+1,240% +$426 ﹤0.01% 5103
2025
Q2 		$37 Buy
+5
New +$45 ﹤0.01% 5198
2024
Q4 		– Sell
-402
Closed -$2.53K – 5733
2024
Q3 		$2.53K Sell
402
-569
-59% -$3.74K ﹤0.01% 4756
2024
Q2 		$6.15K Buy
971
+536
+123% +$3.64K ﹤0.01% 4484
2024
Q1 		$3.57K Buy
435
+433
+21,650% +$3.68K ﹤0.01% 4597
2023
Q4 		$17 Sell
2
-5
-71% -$45 ﹤0.01% 5246
2023
Q3 		$90 Sell
7
-17
-71% -$246 ﹤0.01% 4871
2023
Q2 		$383 Buy
+24
New +$383 ﹤0.01% 4847

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Fidelity Investments's NVCT Position: Q1 2026 in Review

Fidelity Investments increased its Nuvectis Pharma (NVCT) stake by 5% in Q1 2026, buying an estimated $3.07K and bringing the position to 7,568 shares worth $58.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.

Fidelity Investments first reported a position in NVCT in Q2 2023 and has held it in 10 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Fidelity Investments held 7,568 shares of Nuvectis Pharma worth $58.5K as of Q1 2026.
  • Fidelity Investments bought 358 Nuvectis Pharma shares in Q1 2026, an estimated $3.07K.
  • Nuvectis Pharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4059 holding.
  • Fidelity Investments first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 10 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.